Back to Agenda
Session 4. ASEAN Townhall : What is the Influence of Emerging Regulatory Strategies and Trends on the Surveillance of Medicines after They Have Been Approved?
Session Chair(s)
Thean Soo Lo
Regulatory Affairs Management Consultant, Singapore
Helene Sou, MSc, RAC
Global Regulatory Policy and Innovation
Takeda Pharmaceutical Company Limited., Singapore
Speaker(s)
A Comprehensive Approach to the Benefit-Risk Assessment of New Drugs throughout Its Lifecycle
Muzzaffar Halli
Novo Nordisk, Malaysia
Senior Manager RA and PV
Asmaa Asim, MBA
Organon Asia Pacific Pte Ltd, Singapore
Director Regulatory Affairs and Pharmacovigilance
A New Era of Pharmacovigilance – Learnings and Opportunities (Singapore’s Perspective)
Sreemanee Raaj Dorajoo, PhD
Health Sciences Authority (HSA), Singapore
Senior Data Analyst, Vigilance and Compliance Branch
Marakot Papassiripan
Thai FDA, Thailand
Pharmacist, Professional level Biological product sub-div Bureau of Drug Control
MA. THERESA. PIA C. YAP
FDA Philippines, Philippines
Food-Drug Regulations Officer II – IV, LRD, CDRR
Tri Asti Isnariani, MPharm
Badan Pengawas Obat dan Makanan (BPOM), Indonesia
Director of Drug, Narcotics, Psychotropics, Addictive Substances Standardization
Have an account?